Previous 10 | Next 10 |
The stock market is undergoing some distribution. During these periods of time, stock selection is even more important. The POWR Ratings can help you identify ones that are performing well and avoid those with poor prospects. Here are five stocks the POWR Ratings have recently downgraded. ...
EMERYVILLE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology , Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, p...
EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-foun...
I first covered the immune-oncology company Gritstone Oncology ( GRTS ) following the GRANITE phase 1 results which illustrated both safety and clinical benefit in a very small set of 5 heavily pre-treated patients representing different tumor types and varying dose levels. As a reminder the...
Gritstone Oncology (NASDAQ: GRTS ) : Q2 GAAP EPS of -$0.69 beats by $0.02 . More news on: Gritstone Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
EMERYVILLE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the second quarter ended June 3...
EMERYVILLE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced presentations at two upcoming investor conferences in ...
Like most small cap biotech investors I’m always looking for stocks that sell off following early phase clinical trial results although an efficacy signal is present and investment thesis intact. It is not surprising that these sell-the-news events occur as short term biotech traders ...
Gainers: Equillium (NASDAQ: EQ ) +220% . More news on: Equillium, Inc., electroCore, Inc., WiMi Hologram Cloud Inc., Stocks on the move, , Read more ...
Thinly traded micro cap Gritstone Oncology (NASDAQ: GRTS ) slumps 32% premarket on increased volume on the heels of its presentation of interim results from two Phase 1 clinical trials, GRANITE and SLATE, evaluating personalized and off-the-shelf neoantigen therapeutic vaccine ...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...